DEA Compliance for Telehealth Ketamine Prescribing

The Drug Enforcement Administration sits at the center of legal telehealth ketamine prescribing. Any provider issuing a ketamine prescription via telemedicine must navigate DEA regulations carefully. This article explains what those regulations require, how they have evolved, and what compliant prescribing looks like in practice.

Ketamine's DEA Classification

Ketamine is a Schedule III controlled substance under the Controlled Substances Act. It has accepted medical uses—most prominently as an anesthetic and, more recently, as an off-label treatment for depression and other psychiatric conditions. Schedule III drugs have lower potential for abuse than Schedule I or II drugs, but DEA regulations still govern how they can be prescribed and dispensed.

Every practitioner who prescribes ketamine must hold a DEA registration. DEA registrations are specific to a physical address and practice type. A prescriber working for a telehealth platform must have their own DEA registration, and the platform itself may need registrations depending on its business structure.

The Ryan Haight Act Requirement

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 established a fundamental barrier: a practitioner cannot prescribe a Schedule II-V controlled substance to a patient for whom they have not conducted at least one in-person medical evaluation. This requirement applied regardless of whether the subsequent prescription was issued electronically or via telehealth.

The Act contained several exceptions to this in-person requirement:

• The prescription is issued by a hospital or clinic
• The prescription is issued during an "in-person medical evaluation conducted via telemedicine" in cases where the patient is at a DEA-registered hospital or clinic with a DEA-registered practitioner physically present
• The practitioner is on duty for the Indian Health Service
• The patient is in a hospital or residential treatment facility

None of these exceptions generally applied to the consumer telehealth model of patients at home receiving their first evaluation via video. This effectively prohibited the direct-to-consumer telehealth ketamine model under the original Act.

The COVID-19 Exemptions

The landscape changed dramatically in March 2020. The DEA issued a series of blanket exemptions under the public health emergency declaration, authorizing practitioners to prescribe Schedule II-V controlled substances to patients they had not seen in person, provided the prescription was issued for a legitimate medical purpose and documentation requirements were met.

These exemptions did not distinguish between drug classes—meaning Schedule II opioids and Schedule III ketamine were both covered. For telehealth ketamine providers, the exemptions created the legal basis for the entire direct-to-consumer model.

What the Exemptions Required

Compliant prescribing under the COVID exemptions required:

• A valid patient-provider relationship established via telemedicine
• Prescribing for a legitimate medical purpose in the usual course of professional practice
• Use of the state's PDMP before prescribing in states where PDMP use is required
• Documentation that the prescription was issued under the telehealth exemption
• The practitioner maintaining records consistent with DEA requirements

The Path to Permanent Rules

The DEA's COVID exemptions were always intended to be temporary. As the public health emergency wound down, the DEA began the rulemaking process to establish permanent telemedicine prescribing regulations.

The 2023 Proposed Rules

In 2023, the DEA published two proposed rules on telemedicine controlled substance prescribing:

1. A framework for telemedicine prescribing without prior in-person evaluation for Schedule III-V controlled substances in certain circumstances
2. A special registration framework for providers meeting eligibility requirements

The proposed rules generated significant public comment—over 38,000 submissions—and were criticized by telehealth providers as too restrictive. The DEA withdrew the proposed rules for revision and issued further extensions of the COVID exemptions while rulemaking continued.

The Special Registration Concept

The SUPPORT Act of 2018 directed the DEA to create a "telemedicine prescribing registration" for practitioners who meet certain criteria, allowing them to prescribe controlled substances via telemedicine without an in-person visit. This registration has been under development for years. Key elements under discussion include:

• Eligibility criteria for practitioners
• Patient identity verification requirements
• Limits on which conditions or drug classes qualify
• Coordination with state PDMPs
• Record-keeping and audit requirements

Until this registration is finalized and implemented, telehealth ketamine prescribing remains legally grounded in the extended COVID exemptions. For more on how these regulations vary across states, see our state regulations overview.

What Compliant Telehealth Ketamine Prescribing Looks Like

A DEA-compliant telehealth ketamine practice maintains the following elements:

Provider DEA Registration

Every prescribing provider must hold a current DEA registration. For a telehealth practice, this registration is typically issued to the practice address. Providers must renew their registration every three years.

State PDMP Consultation

Most states require prescribers to query the state PDMP before issuing a controlled substance prescription. This check identifies whether the patient has received other controlled substance prescriptions from multiple providers—a potential indicator of misuse or diversion. Compliant providers check the PDMP before the first prescription and at regular intervals thereafter.

Schedule III Prescription Requirements

Ketamine prescriptions must comply with Schedule III requirements:

• Written or electronic prescriptions (verbal prescriptions require written confirmation within 7 days)
• The prescription must include the patient's full name and address, the drug name and strength, quantity, directions for use, and the prescriber's name, address, and DEA number
• Schedule III prescriptions may be refilled up to 5 times within 6 months

Record-Keeping

DEA regulations require practitioners to maintain records of all controlled substance prescriptions for at least 2 years. These records must be available for inspection upon request.

Avoiding Diversion

Providers must take steps to prevent diversion—the transfer of a controlled substance prescription to someone other than the intended patient. This includes conducting thorough intake evaluations, monitoring for behavioral signs of misuse, and not prescribing quantities beyond what is needed for legitimate treatment.

Red Flags for DEA Non-Compliance

When evaluating a telehealth ketamine provider, these practices should raise concerns about regulatory compliance:

• No PDMP check mentioned in the intake or prescribing process
• Providers who cannot confirm they hold current DEA registrations
• Platforms that do not conduct clinical video evaluations before prescribing
• Prescriptions issued for quantities that seem excessive relative to the treatment protocol
• Lack of any follow-up or monitoring after initial prescribing

The telehealth ketamine industry's credibility—and long-term survival—depends on providers maintaining rigorous compliance with DEA requirements. For patients, choosing a provider with clear compliance practices is not just about legal technicalities; it reflects the overall quality of the clinical program. For more on evaluating providers, see what to look for in a telehealth ketamine provider.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service